A modern view of the necessity for adjuvant chemotherapy in patients with colorectal cancer after radical resection of metachronous metastases. Analysis of clinical guidelines of oncology communities

Résumé fourni par la source

Nowadays, the standard treatment option for patients with resectable metastases of colorectal cancer (CRC) is surgical treatment followed by adjuvant chemotherapy (ACT) or perioperative chemotherapy for 6 months, if ACT was not previously performed or more than 12 months have passed since its end. However, ACT does not demonstrate statistically significant improvement in overall survival in such patients. Additionally, we will analyze relevant trials to identify patient subgroups that are likely to benefit from ACT. In this review, we analyze the difference between recent national and foreign clinical guidelines in treatment strategy of patients after radical resection of metachronous metastases of CRC and the results of clinical studies that have become the evidence base for the use of ACT.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.